Myeloma Institute wins $18M grant
The US Myeloma Institute for Research and Therapy, a part of theArkansas Cancer Research Center at the University of Arkansas for Medical Sciences, has received a US National Cancer Institute grant worth nearly $18 million, one of the largest awards ever given to the UAMS.
In addition, the Institute recently: marked a milestone of performing 5,000 stem-cell transplants; will be establishing an endowed chair for myeloma research named in honor of its director, Bart Barlogie; and will be moving into new facilities to allow the Institute to expand its clinical and research capabilities.
The grant will fund an ongoing comprehensive research program, entitled Growth Control of Multiple Myeloma, and will be distributed over a five-year period, concluding in June 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze